Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. All subjects must have a diagnosis of probable Alzheimer's disease based on NIA-AA criteria (2018). If subject biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria~2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)~3. Subjects exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior~4. A score of 0 to 20 on the Mini-Mental State Exam (MMSE) and require moderate to full assistance with activities of daily living~5. Subjects who read, understand, and provide written informed consent, or who have a LAR to provide consent on their behalf~6. Subjects who are deemed to be medically appropriate for study participation by the principal investigator~7. Participants who agree to use a medically acceptable and effective birth control method~Exclusion Criteria:~1. Subjects with dementia or other memory impairment not due to probable AD.~2. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function.~3. Subjects with agitation caused by acute intoxication.~4. Subjects with significant risk of suicide or homicide per the investigator's assessment.~5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (\>5 years) history of stroke may be included, regardless of size/location.~6. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia.~7. Subjects with laboratory or ECG abnormalities.~8. Subjects who have received an investigational drug within 30 days prior to Screening.~9. Subjects who are currently suffering from substance abuse.~10. Subjects with a potential cause for delirium (relatively recent onset agitation and dementia)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1- 40 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 40 Micrograms Dexmedetomidine
- Cohort 2- 60 Micrograms (Type: EXPERIMENTAL): Sublingual film containing 60 Micrograms Dexmedetomidine
- Placebo (Type: PLACEBO_COMPARATOR): Sublingual Placebo film

Based on this trial design, predict the completion outcome and termination type (if applicable).